On Monday, Atossa Therapeutics Inc (NASDAQ: ATOS) opened lower -3.35% from the last session, before settling in for the closing price of $0.70. Price fluctuations for ATOS have ranged from $0.66 to $2.31 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Company’s average yearly earnings per share was noted -27.50% at the time writing. With a float of $129.14 million, this company’s outstanding shares have now reached $129.17 million.
In an organization with 15 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Atossa Therapeutics Inc (ATOS) Insider Updates
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Atossa Therapeutics Inc is 0.02%, while institutional ownership is 27.66%. The most recent insider transaction that took place on Mar 26 ’25, was worth 7,000. In this transaction Director of this company bought 10,000 shares at a rate of $0.70, taking the stock ownership to the 10,257 shares. Before that another transaction happened on Apr 10 ’24, when Company’s Director bought 25,000 for $1.77, making the entire transaction worth $44,250. This insider now owns 25,000 shares in total.
Atossa Therapeutics Inc (ATOS) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around -27.50% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -11.87% during the next five years compared to 36.92% growth over the previous five years of trading.
Atossa Therapeutics Inc (NASDAQ: ATOS) Trading Performance Indicators
Check out the current performance indicators for Atossa Therapeutics Inc (ATOS). In the past quarter, the stock posted a quick ratio of 14.99.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.20, a number that is poised to hit -0.06 in the next quarter and is forecasted to reach -0.29 in one year’s time.
Technical Analysis of Atossa Therapeutics Inc (ATOS)
Let’s dig in a bit further. During the last 5-days, its volume was 0.52 million. That was inferior than the volume of 0.65 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 12.30%. Additionally, its Average True Range was 0.05.
During the past 100 days, Atossa Therapeutics Inc’s (ATOS) raw stochastic average was set at 1.29%, which indicates a significant decrease from 11.73% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 49.53% in the past 14 days, which was lower than the 57.49% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.7867, while its 200-day Moving Average is $1.1585. However, in the short run, Atossa Therapeutics Inc’s stock first resistance to watch stands at $0.6967. Second resistance stands at $0.7206. The third major resistance level sits at $0.7339. If the price goes on to break the first support level at $0.6595, it is likely to go to the next support level at $0.6462. Assuming the price breaks the second support level, the third support level stands at $0.6223.
Atossa Therapeutics Inc (NASDAQ: ATOS) Key Stats
There are currently 129,170K shares outstanding in the company with a market cap of 86.92 million. Presently, the company’s annual sales total 0 K according to its annual income of -30,090 K. Last quarter, the company’s sales amounted to 0 K and its income totaled -7,230 K.
